Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
Active, not recruiting · NCT05585580 · Registry updated 2026-05-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Active, not recruiting | Phase 2 | 2026-05-26 | NCT05585580 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Qilu Hospital of Shandong University | 249 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Linyi Cancer Hospital | Linyi | China | 19 |
| Qilu hospital of Shandong univertisy | Jinan | China | 4 |
| Qingdao Municipal Hospital（Group） | Qingdao | China | 1 |
| Shandong Provincial Hospital Affiliated to Shandong First Medical University | Jinan | China | 5 |
| The Affiliated Hospital of Qingdao University | Qingdao | China | 50 |
| The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital) | Jinan | China | 3 |
| Yantai Yuhuangding Hospital | Yantai | China | 30 |